Oncolytics Biotech
ONCY
28 hedge funds and large institutions have $1.86M invested in Oncolytics Biotech in 2019 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 4 closing their positions.
729% more capital invested
Capital invested by funds: $225K → $1.86M (+$1.64M)
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
33% more funds holding
Funds holding: 21 → 28 (+7)
0.05% less ownership
Funds ownership: 1.58% → 1.53% (-0.05%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$54.9K |
| 2 |
CIBC World Market
Toronto,
Ontario, Canada
|
+$19.4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$17.6K |
| 4 |
Jane Street
New York
|
+$16.4K |
| 5 |
CGA
Crescent Grove Advisors
Lake Forest,
Illinois
|
+$12.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$70.8K |
| 2 |
Renaissance Technologies
New York
|
-$22K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$14.4K |
| 4 |
MFG
Magnus Financial Group
New York
|
-$14K |
| 5 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$2.91K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Renaissance Technologies
New York
| – | -$22K | -37,751 | Closed |
|
|
MFG
27
Magnus Financial Group
New York
| – | -$14K | -25,000 | Closed |
|
|
VCP
28
Verus Capital Partners
Scottsdale,
Arizona
| – | +$59 | +52 | New |
|
ONCY Hedge Fund Activity: Q4 2019 in Review
28 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q4 2019, worth a combined $1.86M — up 729% from $225K a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ONCY positions and 4 closed out — a net gain of 7 holders — while 7 added to existing stakes and 4 trimmed.
The largest buyer was Royal Bank of Canada, adding an estimated $54.9K. The largest seller was Morgan Stanley, cutting an estimated $70.8K.
- 28 institutional investors held Oncolytics Biotech (ONCY) as of Q4 2019, up from 21 in Q3 2019.
- Funds reported $1.86M of Oncolytics Biotech stock for Q4 2019, up 729% quarter-over-quarter.
- 11 funds opened new Oncolytics Biotech positions in Q4 2019 and 4 closed out, a net change of +7 holders.
- The largest Oncolytics Biotech buyer in Q4 2019 was Royal Bank of Canada, an estimated $54.9K added.
- The largest Oncolytics Biotech seller in Q4 2019 was Morgan Stanley, an estimated $70.8K sold.
Based on aggregated 13F filings for Q4 2019.